Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial

Authors:

Abstract
The vaccine candidate CVnCoV (CUREVAC) showed surprisingly low efficacy in a recent phase 3 trial compared with other messenger RNA (mRNA) vaccines. Here we show that the low efficacy follows from the dose used and the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants and is predicted by the neutralizing antibody response induced by the vaccine.
All Related Versions
Funding Information
  • Australian government Medical Research Future Fund (GNT2002073, MRF2005544, MRF2005760, MRF2007221)
  • NHMRC (GNT1149990)

This publication has 9 references indexed in Scilit: